bispecific antibody
News/ News/ News/ Oncology/ R&D
ASH: J&J makes case for just-filed GPRC5D drug talquetamab
Phil Taylor
bispecific antibody, GPRC5D, Haematology, Johnson & Johnson, multiple myeloma, Oncology
0 Comment
News/ News/ News/ Oncology/ R&D
Little Summit Therapeutics spends big bucks to rebuild pipeline
Phil Taylor
Akeso, bispecific antibody, immuno-oncology, licensing, Non-small cell lung cancer, Oncology, Summit Therapeutics
0 Comment
Market Access/ News/ News/ News/ Oncology
J&J nabs FDA okay for BCMA bispecific Tecvayli
Phil Taylor
BCMA, bispecific antibody, Haematology, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology, regulatory approval, Tecvayli
0 Comment
News/ News/ News/ Oncology/ R&D
Gilead pledges $1.76bn to MacroGenics for bispecific cancer antibody
Phil Taylor
bispecific antibody, Gilead Sciences, Haematology, MacroGenics, Oncology, partnering
0 Comment
Market Access/ News/ News/ News/ Oncology
CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision
Phil Taylor
bispecific antibody, CHMP, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology, teclistamab, Tecvayli
0 Comment
Roche trumpets new glofitamab data in lymphoma at ASCO
Phil Taylor
bispecific antibody, diffuse B-Cell lymphoma, epcoritamab, glofitamab, non-Hodgkin lymphoma, Polivy, Roche
0 Comment
AACR: Affimed builds case for natural killer cell therapy
Phil Taylor
Affimed, bispecific antibody, classical Hodgkin lymphoma, immuno-oncology, natural killer cell, non-Hodgkin lymphoma, Oncology
0 Comment
Sanofi places $75m bet with ABL on popular Parkinson’s drug target
Phil Taylor
ABL Bio, bispecific antibody, Parkinson's disease, partnering, Sanofi
0 Comment